Stock Markets February 10, 2026

Nektar reports durable atopic dermatitis responses in REZOLVE-AD maintenance phase

Rezpegaldesleukin shows sustained efficacy at one year across monthly and quarterly dosing; company eyes Phase 3 and 2029 BLA target

By Derek Hwang NKTR
Nektar reports durable atopic dermatitis responses in REZOLVE-AD maintenance phase
NKTR

Nektar Therapeutics said patients who continued treatment with rezpegaldesleukin after induction sustained high response rates at week 52 in the Phase 2b REZOLVE-AD trial, with both monthly and quarterly maintenance regimens. The stock rose modestly on the news as the company prepares to advance to a pivotal Phase 3 program and targets a Biologics License Application submission in 2029.

Key Points

  • REZOLVE-AD maintenance data showed 71% (monthly) and 83% (quarterly) preserved EASI-75 responses at week 52, and 85% (monthly) and 63% (quarterly) preserved vIGA-AD 0/1 responses.
  • The global Phase 2b study enrolled 393 patients; responders after a 16-week induction were re-randomized to monthly or quarterly maintenance for 36 additional weeks to produce the 52-week data.
  • Nektar reported no new safety signals in the maintenance period and a 3.5% discontinuation rate due to adverse events; the company plans to advance to a pivotal Phase 3 program and aims for a 2029 BLA submission.

Nektar Therapeutics (NASDAQ:NKTR) saw its shares tick up 3% Tuesday morning after the company released maintenance-phase data from REZOLVE-AD, its global Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.

The clinical-stage biotech reported that patients who continued on rezpegaldesleukin after an induction period maintained strong efficacy outcomes at week 52 with both monthly and quarterly dosing schedules. According to the company, 71% of patients on 24 µg/kg monthly dosing and 83% on 24 µg/kg quarterly dosing preserved EASI-75 responses at week 52. On the vIGA-AD 0/1 measure, 85% of monthly-dosed patients and 63% of quarterly-dosed patients maintained response through week 52.

In addition to those maintained response rates, Nektar reported increases in EASI-100 rates, describing up to a 5-fold rise in complete lesion clearance relative to earlier points in the study.

The REZOLVE-AD trial enrolled 393 patients with moderate-to-severe atopic dermatitis. After a 16-week induction phase, participants who achieved at least a 50% improvement in EASI scores were re-randomized to continue rezpegaldesleukin either monthly or quarterly for an additional 36 weeks, yielding the 52-week maintenance dataset now reported.

On safety, the company said the maintenance profile of rezpegaldesleukin was consistent with prior results and that no new safety concerns emerged during the maintenance period. Across aggregated patients, the discontinuation rate due to adverse events was 3.5%.

“These data validate the novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator,” the company said, adding that the durability of maintained response rates supports advancement to a pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing.

Nektar also indicated its aim to file a Biologics License Application for rezpegaldesleukin in 2029. The company’s statement tied the maintenance durability observed in REZOLVE-AD to plans for a pivotal study that would evaluate the same maintenance regimens.

Market reaction to the release was modest, with NKTR shares rising about 3% on the session when the data were disclosed. Investors and market participants will likely focus on the design and eventual outcomes of the planned pivotal Phase 3 program and the pathway toward the 2029 BLA target as next milestones.


Summary

Nektar reported durable responses for rezpegaldesleukin in the maintenance portion of its Phase 2b REZOLVE-AD trial. High rates of maintained EASI-75 and vIGA-AD 0/1 responses were observed at week 52 with both monthly and quarterly 24 µg/kg dosing. Safety remained consistent with prior reports and discontinuations due to adverse events totaled 3.5% across aggregated patients. The company said the results support moving to a pivotal Phase 3 program and plans a BLA submission in 2029.

Risks

  • Advancement to regulatory submission depends on success of the planned pivotal Phase 3 program - the REZOLVE-AD maintenance results support advancement but do not by themselves guarantee Phase 3 outcomes or approval (impacts biotech and regulatory sectors).
  • Although no new safety concerns were identified during the maintenance period, there was a 3.5% discontinuation rate due to adverse events among aggregated patients, which could influence tolerability assessments in larger pivotal studies (impacts clinical development and healthcare sectors).
  • The company’s 2029 BLA target depends on subsequent development steps and timing of the pivotal program; the timeline is therefore subject to change based on Phase 3 design and outcomes (impacts pharmaceutical regulatory planning and markets).

More from Stock Markets

Rolls-Royce Poised to Announce Up to £1.5 Billion Share Buyback Alongside Annual Results Feb 22, 2026 DAE Capital Nears Purchase of Macquarie AirFinance, Sources Say Feb 22, 2026 S&P 500 Shows Signs of Tightening Range; Strategist Sees Potential for a Big Move Feb 22, 2026 Supreme Court to Clarify Reach of Helms-Burton Act in Multi-Billion Dollar Cuba Claims Feb 22, 2026 Switzerland Pulling Ahead in Early Economic Gains from AI Feb 22, 2026